| CCM OPEN HF Registry | — | Impulse Dynamics | <1 mi |
| Assessment of CCM in HF With Higher Ejection Fraction | N/A | Impulse Dynamics | <1 mi |
| Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment | N/A | Aventyn, Inc. | <1 mi |
| Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387 | Phase 2/3 | Kiniksa Pharmaceuticals International, plc | <1 mi |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | <1 mi |
| The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves). | N/A | Mayra Guerrero | <1 mi |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | N/A | Cardiac Dimensions, Inc. | <1 mi |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Phase 3 | Novo Nordisk A/S | <1 mi |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | <1 mi |
| A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | Phase 3 | Colorado Prevention Center | <1 mi |
| Product Surveillance Registry | — | Medtronic | <1 mi |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | N/A | Shockwave Medical, Inc. | <1 mi |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | <1 mi |
| Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure | N/A | Procyrion | <1 mi |
| Alleviant ALLAY-HF Study | N/A | Alleviant Medical, Inc. | <1 mi |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | <1 mi |
| Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women | Phase 2 | Arizona State University | <1 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | <1 mi |
| American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study) | — | University of New Mexico | <1 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Phase 2/3 | CSL Behring | <1 mi |
| Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation | Phase 3 | University of Chicago | <1 mi |
| A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists | Phase 3 | Colorado Prevention Center | <1 mi |
| Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure | N/A | Abbott Medical Devices | <1 mi |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | <1 mi |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | — | Duke University | <1 mi |
| Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation | N/A | Arga Medtech SA | <1 mi |
| REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | — | Medtronic Cardiovascular | <1 mi |
| Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions | N/A | Aventyn, Inc. | <1 mi |
| Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block | — | The Hospital for Sick Children | <1 mi |
| Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment | — | Montefiore Medical Center | <1 mi |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Phase 3 | X4 Pharmaceuticals | <1 mi |
| Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery | Phase 4 | Phoenix Children's Hospital | <1 mi |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | <1 mi |
| Danon Disease Natural History Study | — | Rocket Pharmaceuticals Inc. | <1 mi |
| PARTNER 3 Trial - Aortic Valve-in-Valve | N/A | Edwards Lifesciences | <1 mi |
| Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina. | Phase 2 | XyloCor Therapeutics, Inc. | <1 mi |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | <1 mi |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | <1 mi |
| A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System | N/A | Biosense Webster, Inc. | <1 mi |
| A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma | — | Children's Oncology Group | <1 mi |
| AMEND TS Early Feasibility Study | N/A | Valcare Medical Ltd. | <1 mi |
| ELEVATE-HFpEF Clinical Study | N/A | Medtronic Cardiac Rhythm and Heart Failure | <1 mi |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Phase 2/3 | Kardigan, Inc. | <1 mi |
| Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement | N/A | University of British Columbia | <1 mi |
| Transition to KPL-387 Monotherapy Dosing & Administration Study | Phase 2 | Kiniksa Pharmaceuticals International, plc | <1 mi |
| BiVACOR® Total Artificial Heart Early Feasibility Study | N/A | BiVACOR Inc. | <1 mi |
| PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III | N/A | Endotronix, Inc. | <1 mi |
| CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) | Phase 3 | Cardiol Therapeutics Inc. | <1 mi |
| The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) | Phase 2 | Milestone Pharmaceuticals Inc. | <1 mi |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | <1 mi |
| A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | Phase 3 | Colorado Prevention Center | <1 mi |
| His-Bundle Corrective Pacing in Heart Failure | N/A | University of Rochester | <1 mi |
| Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure | N/A | Boston Scientific Corporation | <1 mi |
| EFS of the DUO System for Tricuspid Regurgitation | N/A | CroiValve Limited | <1 mi |
| Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) | N/A | University of Michigan | <1 mi |
| Abbott Cephea Mitral Valve Disease Registry | — | Abbott Medical Devices | <1 mi |
| ATLAS (AltaValve) Pivotal Trial | N/A | 4C Medical Technologies, Inc. | <1 mi |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | <1 mi |
| The ENCIRCLE Trial | N/A | Edwards Lifesciences | <1 mi |
| Cephea Early Feasibility Study | N/A | Abbott Medical Devices | <1 mi |
| The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients | Phase 4 | University of Rochester | <1 mi |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | <1 mi |
| The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment | — | BillionToOne Inc. | <1 mi |
| ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety) | — | Emory University | <1 mi |
| Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation | N/A | Medtronic Cardiovascular | <1 mi |
| Functional ElectroAnatomiC Isochronal Late Activation Mapping for Empiric VT Ablation Trial | N/A | University of Arizona | <1 mi |
| Prospective Global Registry for the Study of Chronic Total Occlusion Intervention | — | Minneapolis Heart Institute Foundation | <1 mi |
| BOND: Direct Breastfeeding to Enhance Maternal and Infant Health in Congenital Heart Disease | N/A | Carelon Research | <1 mi |
| Cryoablation for Monomorphic Ventricular Tachycardia (VTS) | N/A | Adagio Medical | <1 mi |
| Prenatally-initiated Psychological Intervention for Mothers of Infants With Congenital Heart Disease (CHD) | N/A | Carelon Research | <1 mi |
| Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED) | — | VDI Technologies | <1 mi |
| The WiSE®-UP Study (The WiSE System Utilization & Performance Study) | — | EBR Systems, Inc. | <1 mi |
| AngelMed Guardian® System PMA Post Approval Study | — | Angel Medical Systems | <1 mi |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | 3 mi |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | 3 mi |
| An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Phase 3 | Novartis Pharmaceuticals | 3 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | 3 mi |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | 3 mi |
| Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias | — | Heart Rhythm Clinical and Research Solutions, LLC | 3 mi |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | 3 mi |
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Phase 2 | Cytokinetics | 3 mi |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | 3 mi |
| DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting | — | Alnylam Pharmaceuticals | 3 mi |
| LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 | Phase 3 | Tenax Therapeutics, Inc. | 3 mi |
| Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System | N/A | Laplace Interventional, Inc | 3 mi |
| Omega-3D: Omega-3 for Diet-Driven Health Disparities | Phase 2 | University of Arizona | 3 mi |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | N/A | W.L.Gore & Associates | 3 mi |
| Prevail Global Study | N/A | Medtronic Vascular | 3 mi |
| An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis | Phase 2 | Zomagen Biosciences Ltd. | 3 mi |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | 3 mi |
| A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension | Phase 2 | Retension Pharmaceuticals. Inc. | 3 mi |
| PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR | N/A | Edwards Lifesciences | 3 mi |
| CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry | — | Universitätsklinikum Hamburg-Eppendorf | 3 mi |
| An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System | N/A | HighLife SAS | 3 mi |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | Phase 2 | Novo Nordisk A/S | 3 mi |
| CardioFocus HeartLight Post-Approval Study | N/A | CardioFocus | 3 mi |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Phase 3 | Intellia Therapeutics | 3 mi |
| NobleStitch EL STITCH Trial is a PFO Comparative Trial | N/A | Nobles Medical Technologies II Inc | 3 mi |
| A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation | N/A | Biosense Webster, Inc. | 3 mi |
| A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease | N/A | Pulnovo Medical, Inc. | 3 mi |
| Apixaban Versus Warfarin for Left Ventricular Thrombus | Phase 3 | University of Arizona | 3 mi |
| MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions | N/A | Concept Medical Inc. | 5 mi |
| MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels | N/A | Concept Medical Inc. | 5 mi |
| A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF | Phase 3 | AstraZeneca | 5 mi |
| PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | N/A | Kardion Inc | 8 mi |
| Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia | N/A | Mayo Clinic | 8 mi |
| Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator | Phase 4 | University of Rochester | 8 mi |
| Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog | N/A | Mayo Clinic | 8 mi |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | 8 mi |
| Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2) | Phase 2/3 | Thryv Therapeutics, Inc. | 8 mi |
| J-Valve Transfemoral Pivotal Study | N/A | JC Medical, Inc., an affiliate of Edwards Lifesciences LLC | 8 mi |
| Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study | N/A | AtaCor Medical, Inc. | 8 mi |
| AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications | Phase 3 | Novo Nordisk A/S | 8 mi |
| Feasibility and Usability of a Chest-Strap Ambulatory ECG Monitor in Active Individuals in Comparison With a Traditional Ambulatory ECG Patch Monitor (MoMe ARC) | — | Mayo Clinic | 8 mi |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | Phase 3 | Regeneron Pharmaceuticals | 9 mi |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | 16 mi |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Phase 3 | Boehringer Ingelheim | 20 mi |